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Abstract 
Introduction: MicroRNAs (miRNAs) are a set of small single-stranded noncoding 
RNAs with diverse biological functions. As a prototypical hypoxamir, human 
microRNA-210 (hsa-miR-210) is one of the most widely studied miRNAs thus far. In 
addition to its involvement in sophisticated regulation of numerous biological 
processes, miR-210 has also been shown to be associated with the development of 
different human diseases including various types of cancers, cardiovascular and 
cerebrovascular diseases, and immunological diseases. Given its multi-faceted 
functions, miR-210 may serve as a novel and promising theranostic target for 
prevention and treatment of diseases.  
Areas covered: This review aims to provide a comprehensive overview of miR-210, 
the regulation of its expression, biological functions and molecular mechanisms, with 
particular emphasis on its diagnostic and therapeutic potential. 
Expert opinion: Although the exact roles of miR-210 in various diseases have not 
been fully clarified, targeting miR-210 may be a promising therapeutic strategy. 
Further investigations are also needed to facilitate therapeutic-clinical applications of 
miR-210 in human diseases.  
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Article highlights  
• miRNAs perform diverse biological functions primarily by post-transcriptionally 
silencing target genes.  
• The capacity to regulate a wealth of target mRNAs enables miR-210 to control 
a signaling network involved in multiple biological processes. 
• There seems to be a general consensus that dysregulation of miR-210 
expression plays a pivotal and causal role in numerous human diseases. 
• miR-210, especially circulating miR-210, may represent a viable diagnostic 
biomarker for early detection or differential diagnosis of various diseases while 
this miRNA also shows promise as a prognostic factor. However its specific 
role may vary depending on the physio-pathological context. 
• miR-210 has the potential to be a promising therapeutic target, despite its 
limitations. 
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1. Introduction 
MicroRNAs (miRNAs) are tiny, evolutionarily conserved noncoding RNAs and have 
the essential function of gene regulation both in plants and animals [1]. As is 
described in the latest release of miRBase, there are 1881 precursors and 2588 
mature miRNAs in human genome (miRBase Release 21, http://www.mirbase.org) 
[GRCh38]. Accumulating evidence suggests that extracellular miRNAs may originate 
from cell lysis in cell apoptosis or necrosis, chronic inflammation, and injury, or from 
the short half-life cells [2]. miRNAs can also be secreted into circulation via 
microvesicle such as exosomes [3]. Furthermore, a high-density lipoprotein pathway 
may be another distinct mechanism for exporting miRNAs [4]. As a result, miRNAs 
are readily detectable in serum and other body fluids, and exhibit striking stability 
compared with mRNAs and other long RNAs. Biogenesis of miRNA consists of 
multiple consecutive stages and mature single-stranded miRNA forms RNA-induced 
silencing complex (RISC) with proteins of Argonaut (Ago) family, especially Ago-2 [5]. 
RISC is mainly responsible for silencing the gene at the post-transcriptional level. The 
miRNA base-pairs with target mRNA achieve gene silencing by mRNA cleavage or 
translational repression. It is now widely acknowledged that the specificity of miRNA 
targeting depends on how complementary the ‘seed’ sequence (nucleotides 2-8 from 
5’ end of the miRNA) and the ‘seed-match’ sequence (usually in the 3’ untranslated 
region (UTR) of the target mRNA) are [6]. However, miRNA has recently been 
demonstrated to bind to either the 5’ UTRs of its target gene [7] or even the gene 
coding region [8]. Surprisingly, some miRNAs have also been found to activate rather 
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than inhibit gene expression, or enhance protein translation [9]. Usually, one miRNA 
has more than one target mRNA, and one mRNA is targeted by more than one 
miRNA [10].This phenomenon results in formation of an intricate regulatory network 
that plays an important role in a myriad of biological processes, such as cellular 
proliferation, apoptosis, differentiation, and angiogenesis. 
Hypoxia is a common causative hallmark of pathological conditions including tissue 
ischemia and solid tumours. Hypoxic adaptation is favorable to aerobic mammalian 
cells in the short term, whereas chronic hypoxia may cause adverse pathological 
consequences [11]. Mounting data demonstrate that under hypoxia, miRNAs are 
involved in regulating both upstream and downstream signaling of hypoxia-inducible 
transcription factor (HIF) pathways [12, 13]. Among them, human miR-210, also 
known as hypoxamir, is regarded as the most important one and appears to be a HIF 
target gene highly upregulated by both HIF-1α and HIF-2α in various cell types [12, 
14]. In fact, miR-210 is involved in numerous biological processes, especially the 
pathogenesis of a variety of diseases. This review will focus on analyzing the 
biological functions and molecular mechanisms of miR-210, analyze its association 
with various diseases and evaluate its potential clinical applications in diagnosis and 
treatment of human diseases. 
 
2. Biology of miR-210 
The stem-loop form of miR-210 (pre-miRNA) is contained in the intron region of a 
noncoding RNA (pri-miRNA), which is transcribed from AK123483; AK123483 gene is 
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on chromosome 11, in the 11p15.5 region [14]. miR-210 genomic sequences, 
especially coding sequence and the hypoxia response element (HRE) site, are 
evolutionarily conserved across species, suggesting functional importance of these 
sequence [12]. There are overwhelming data demonstrating that miR-210 is 
ubiquitously expressed in hypoxic cell and tissue types including a variety of cancer 
cells, lymphocytes, myeloid cells, and hematopoietic stem cells [11, 15-19]. Aberrant 
miR-210 overexpression has been demonstrated during fibroblast senescence, 
causing reduction of cell proliferation and enhancement of DNA damage [20]. In 
addition, miR-210 may also be upregulated after treatment, such as photodynamic 
therapy [21]. Surprisingly, the elevated expression of miR-210 does not return to its 
normoxic level until 24 hours after hypoxic exposure [22], which can lead to an 
exceptionally long half-life. However, no evidence suggests the long-lasting miR-210 
expression as a ‘buffer’ that gradually releases the suppression of its targets, thus 
easing the transition from hypoxia to normoxia for the cell. With respect to how 
circulating miR-210 coordinates hypoxic adaptation across anatomically distinct cells, 
Hale et al. [23] have recently reported a pivotal molecular switch, prolyl-hydroxylation 
of Ago-2 which can control miR-210’ release and its activity upon uptake into recipient 
cells. miR-210 can also upregulate the mammalian target of rapamycin (mTOR) 
pathway, an essential driver of senescence [24]. This, together with DNA damage and 
oxidative stress, may contribute to the process of senescence. 
 
3. Regulation of miR-210 expression 
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Figure 1 summarizes regulation of miR-210 expression. As is the case with a 
number of classic HIF-1α-regulated genes, HIF-1α binds directly to a highly 
conserved HRE on the proximal miR-210 promoter [12]. miR-210 has also been 
documented to be induced by oxidative stress [25] under direct control of HIF-1α [26]. 
While HIF-1α pathway is regarded as a sufficient and predominant regulator of 
miR-210 expression and a positive feed-forward loop between them has been shown 
[12, 25, 27-29], HIF-2α-dependent induction of miR-210 has also been recognized [30, 
31]. Interestingly, miR-210 may contribute to activation and stabilization of HIF-1 by 
inhibiting succinate dehydrogenase complex subunit D (SDHD, a part of complex II) in 
respiratory chain [32].  
Additionally, several emerging transcriptional factors have been confirmed to drive 
miR-210 expression in a tissue- or a cell type-specific manner, such as Oct2/4, E2F, 
and PPARγ [33, 34]. Mutharasan et al. first suggested that miR-210 was upregulated 
in hypoxic cardiomyocytes through protein kinase B (Akt)- and p53-dependent 
pathways [35]. This phenomenon has been shown in both normal and transformed 
cells [36]. A novel transcriptional mechanism has also been revealed: NFkappa B 
transcriptional factor p50 (NFκB1) is an upstream regulator of miR-210 under hypoxia 
and can stimulates miR-210 expression in a fetal sex-dependent manner in placentas 
with maternal obesity [37]. Thus NFκB1 and miR-210 form a positive feedback loop. 
As such, increased miR-210 expression can be observed with the activation of PI3K, 
Akt, ERK, and NFκB/ELK1 pathways by connective tissue growth factor (CTGF, 
namely CCN2, an inflammatory mediator) [38]. Furthermore, Chapoval et al. [39] have 
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first demonstrated that activation of Toll-like receptor (TLR) 3 can significantly 
upregulate miR-210 expression both in TLR3-induced mouse model of PE placentas 
and in human cytotrophoblasts. In addition, miR-210 overexpression occurs via an 
inhibitory-independent mechanism that is modulated by CD63 (cell surface receptor of 
TIMP-1) -TIMP-1 interaction [40].  
Several studies show that miR-210 can stimulate the generation of reactive oxygen 
species (ROS) by targeting complexes I and II of the electron transport chain [19, 32]. 
Its overexpression thus induces accumulation of ROS [20]. Kim et al. [41] conversely 
demonstrated that ROS generation from various sources could induce miR-210 
upregulation in adipose-derived stem cells. These findings suggest the interaction 
between miR-210 and ROS.  
Furthermore, DNA damage can partially modulate the expression of miR-210 [20]. 
Xiong et al. [42] have provided evidence that DNA demethylation may mediate 
miR-210 expression independent of HIF-1α pathway in neural progenitor cells (NPCs) 
under both normoxia and hypoxia conditions. Recently, a report reveals that leukocyte 
DNA methylation induced by exercise training can alter miR-210 gene, subsequently 
influencing expression of its mature miRNA [43]. Also, somatic von Hippel-Lindau 
(VHL) gene may contribute to the induction of miR-210 [44]. Succinate 
dehydrogenase (SDH) deficiency in pheochromocytomas (PCs), paragangliomas 
(PGLs) and gastrointestinal stromal tumours (GISTs) was reported to activate 
miR-210 expression, but the mechanism remains unclear [45].  
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4. Regulation of signaling network by miR-210  
With the development of technology, such as whole transcriptome RNA sequencing 
(RNA-Seq), microarray and in silico, it is possible to identify numerous target genes of 
miR-210. However because miRNAs also regulate protein expression by repressing 
their protein translation without changing their mRNA expression, some bona fide 
targets of miRNA may be undetected by using the above strategies [46]. It has been 
demonstrated that miR-210 plays a critical role in the modulation of several signaling 
pathways including cell proliferation, apoptosis, angiogenesis, DNA damage repair, 
and immune responses as summarized in Figure 2. 
4.1 Signaling pathways of proliferation regulated by miR-210 
Emerging evidence suggests that miR-210 may attenuate cancer cell proliferation 
by suppressing fibroblast growth factor receptor-like 1 (FGFRL1) and inducing cell 
cycle arrest in G1/G0 phase (Figure 1) [47]. It has also been stablished that 
miR-210-mediated downregulation of some cell cycle regulators, especially E2F 
transcription factor 3 (E2F3, a crucial facilitator of cell proliferation), may alter 
centrosome replication in S phase to control cell cycle [26, 48]. Biswas et al. [27] used 
a murine ischemic wound model to further elucidate that miR-210 could limit 
keratinocyte proliferation by knockdown of E2F3 under hypoxia. Furthermore, a 
growing body of evidence suggests that miR-210 overexpression can not only govern 
the onset of mitosis by targeting Cdc25B and Plk1, but also control the mitotic 
progression by mediating Plk1, Cyclin F, Bub1B and Fam83D, inducing G2/M arrest 
and finally cell death in diverse type cells [26, 49]. Similarly, miR-210 may act as an 
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inhibitor on tumour initiation by suppressing homeobox protein Hox-A1 (HOXA1) [12] 
that helps prompt cell survival in a Bcl-2-dependent manner in mammary carcinoma 
cells [50] (Figure 2). Of note, with the development of a tumour, dramatically 
upregulated miR-210 could produce an inhibitory effect [49]. Also, miR-210 
dramatically reduces cellular proliferation rate in senescent human diploid fibroblasts 
by targeting mTOR pathway [20].  
With regard to infection, miR-210 is generally associated with inhibition of 
viral/bacterial replication. For example, miR-210 may function as a suppressor in HBV 
replication via directly targeting the transcripts of hepatitis B virus gene pre-S1 region 
[51]. During chronic Helicobacter pylori infection, miR-210 appears to be 
downregulated, resulting in augmentation of gastric epithelial cell proliferation through 
activating stathmin 1 and dimethyladenosine transferase 1 [52]. 
Nonetheless, contradictory results exist regarding the role of miR-210 in promoting 
or inhibiting cell proliferation. Hypoxia can promote proliferation of various cells via 
HIF-1α and HIF-2α [53], and also upregulate miR-210. This suggests that miR-210 
may participate in cell proliferation. Indeed, miR-210 has been shown to mediate cell 
proliferation by targeting specific proteins such as transferrin receptor 1 (a major 
Iron-uptake protein) under hypoxic microenvironment in tumour [54]. Similar results 
have been shown in the endometriotic cyst stromal cells (ECSCs) where miR-210 
targets signal transducer and activator of transcription 3 (STAT3) [55]. Moreover, by 
downregulating protein tyrosine phosphatase, non-receptor type (PTPN) 1 and 
PTPN2 respectively, miR-210 exhibits an increased proliferation of epithelial ovarian 
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cancer cells and adipose-derived stem cells [41, 56]. As described in some studies, 
miR-210 can boost cell proliferation through activating c-Myc signaling pathway via 
repressing MNT (Max’s next tango, a Max-interacting transcriptional repressor) [31]. 
Since both MYC and miR-210 target E2F3, miR-210 may positively or negatively 
regulate MYC pathway at several points, as a rheostat to fine tune the net output of 
this pathway [27, 29].  
Thus, the relationship between miR-210 and cell proliferation seems to be rather 
complex and the underlying molecular mechanisms remain to be determined.4.2 
Signaling pathways of apoptosis regulated by miR-210 
Apoptosis is the most common form of programmed cell death in multicellular 
organisms in which the caspase family of cysteine proteases are mainly involved in 
the molecular events in the execution phase [57]. Within the caspase family, the 
effector caspases (caspases-3, -6 and -7) fine-tune the demolition stage of apoptosis 
[58]. Cheng et al. [59] first showed that blockade of miR-210 with antisense inhibitor 
could enhance the apoptosis level through inducing caspase-3 activity in HeLa cells. 
Since then, a multitude of similar results were further demonstrated in diverse cell 
types, such as endothelial cells (ECs) [22]. miR-210 overexpression directly inhibits 
the SH2-containing inositol phosphatase 1 (SHIP-1，a lipid phosphatase) and this may 
promote myeloid leukemic growth in CD34+ myelodysplastic syndromes (MDS) cells 
[60] (Figure 2). As presented in a previous study, miR-210 mimics may reduce cell 
death by suppressing both the expression of Bcl-2 adenovirus E1B 19 kDa-interacting 
protein 3protein and the translocation of apoptosis inducing factor (AIF) into nucleus 
D
ow
nl
oa
de
d 
by
 [U
CS
F L
ibr
ary
] a
t 0
8:0
0 0
3 J
uly
 20
16
 
12 
 
in NPCs [61]. Similarly, Jiang et al. [16] identified that miR-210 was a potential 
regulator in the antioxidant stress and anti-apoptosis responses induced by vagus 
nerve stimulation in ischemic stroke rats. Additionally, miR-210 is found to inhibit 
apoptosis by potentially targeting receptor tyrosine kinase ligand EphrinA3 and 
PTP1β in a murine model of myocardial infarction (MI) [29]. Consistent results have 
been demonstrated in human pulmonary vascular smooth muscle cells with 
repression of E2F3 [62], and in ECSCs with activation of signal transducer and 
activator of transcription (STAT) 3 [55]. Yang et al. [63] suggested that knockdown of 
miR-210 could increase apoptosis-inducing factor, mitochondrion-associated 3 
(AIFM3, an apoptotic promoter) expression, robustly inducing cell arrest in the G0/G1 
phase in human hepatoma cells under hypoxia. Finally, the production of ROS 
stimulated by miR-210 [32] could decrease apoptosis. Thus miR-210 mainly 
suppresses apoptosis via its action on many key regulators of apoptosis. 
 On the other hand, miR-210 is also considered as a pro-apoptotic factor. Multiple 
dehydrogenases components, such as SDHD, have been validated as bona fide 
miR-210 targets that participate in mitochondrial dysfunctions in a variety of cell lines 
[32], consequently inducing cellular apoptosis. It has been established that enlarged 
mitochondria with a modified organization of cristae in miR-210-expressing cells is 
associated with an induction of apoptosis. Reportedly, miR-210 may partially 
participate in degradation of Bcl-2 mRNA (an anti-apoptotic factor and a target of 
miR-210), leading to hypoxia-induced apoptosis in insulted neurons [64]. Moreover, 
miR-210 controls mitochondrial function by repressing multiple related mitochondrial 
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targets in various cell lines, such as iron-sulfur cluster scaffold homolog1/2 (ISCU1/2) 
[65] and cytochrome-coxidase assembly protein [19]. As a crucial physiological role of 
MNT is to inhibit apoptosis [66], miR-210 may promote apoptosis via its action on 
MNT. Hence, miR-210 seems to be either cytotoxic or cytoprotective in terms of cell 
apoptosis. 
4.3 Signaling pathways of angiogenesis modulated by miR-210 
Generally, angiogenesis refers to the process of vessel growth, while in the strictest 
sense, it denotes vessel sprouting from pre-existing ones [67]. It is essential for 
embryo development as well as the vascular homeostasis in adults. Angiogenesis is 
normally begun with preliminary destabilization of pre-existing vessels, and this is 
followed by EC proliferation and migration, canalization and eventually stabilization of 
the vessel wall, leading to tube formation [68]. . Since the stimulation of angiogenesis 
is a main biological effect of hypoxia, the unique hypoxamir miR-210 is likely to play a 
role in angiogenesis. Various modes of action for miR-210 in regulating angiogenesis 
are summarized in Figure 1. 
In ECs, vascular endothelial growth factor (VEGF, a powerful angiogenic factor) can 
activate postnatal angiogenesis via upregulating miR-210 [69]. Indeed, miR-210 was 
most predominantly coupled to ‘VEGF, hypoxia and angiogenesis’ in breast cancer, 
which was identified by global testing [70]. By using miR-210 transfection in normal 
endometrial stromal cells, Okamoto et al. further demonstrated that STAT3 could be 
stimulated by miR-210, leading to induction of VEGF production [55]. Similarly, 
evidence was presented that miR-210 up-regulation under normoxic conditions in 
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ECs significantly triggered the formation of capillary-like structures and VEGF-driven 
cell migration, whereas miR-210 blockade under hypoxia markedly inhibited these 
events [22] that are key to the angiogenic process. Moreover, Kosaka et al. [71] first 
suggested that exosomal miR-210 could be horizontally transported from cancer cells 
to ECs via exosomes, which would trigger the angiogenic activity in vitro. More 
recently, in vitro and in vivo experiments in lung adenocarcinoma have substantiated 
that the TIMP-1-induced PI3K/AKT/HIF-1/miR-210/Ephrin A3 pathway promotes 
angiogenesis probably indirectly through an action on the exosomes that have 
proangiogenic properties. On the other hand, overexpression of miR-210 in exosomes 
can increase vessel formation of ECs by repression of anti-angiogenic Ephrin A3 [40]. 
Targeting PTP1β, GPD1L and PHD2, miR-210 can also generate similar effects [29, 
38]. Consistent with these data, miR-210 has been identified as a vital regulator for 
CD34+ cell-induced angiogenesis [72]. Furthermore, WSS25, a sulfated derivative of 
a type of glucan isolated from the well-known Chinese herb Gastrodia elata Bl has 
been reported to be closely correlated to downregulation of miR-210 and upregulation 
of miR-210 target Ephrin A3 in human microvascular endothelial cells , thus blocking 
angiogenesis [73]. Given these proangiogenic roles，studying the function of miR-210 
may help to understand the process of many human diseases. 
4.4 miR-210 and DNA damage repair 
Under hypoxia, DNA repair capacity may be affected by increased genetic instability 
via numerous DNA repair-related genes including MLH1, MSH2 and RAD51 [74], 
where miR-210 is likely to play a functional role (Figure 2). Previous work elucidated 
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that forced miR-210 expression reduced endogenous levels of RAD52 (a 
recombination repair regulator) that assists in loading RAD51 onto DNA to form 
nucleoprotein filaments, resulting in decrease of homology-dependent DNA repair 
activity in response to hypoxic stress [75]. In addition, miR-210 is also implicated in 
double-strand DNA breaks and appearance of a DNA-damage response marker 
(rH2AX foci) in human cells which undergo replicative senescence, subsequently 
aggravating DNA damage [20]. All these findings help to understand the biological 
basis for prompting DNA damage under hypoxia. However, complete function of this 
miRNA has yet to be investigated. 
4.5 miR-210 and immune responses 
miR-210 can also modulate immune responses as shown in Figure 3. Previous 
studies have suggested that cytotoxic T lymphocytes (CTLs) are essential effector 
cells in tumour rejection and important players in host defense against malignancies 
[76]. A recent study revealed that miR-210 could dramatically downregulate tumour 
cell susceptibility to CTL-mediated cell lysis by targeting downstream PTPN1, HOXA1, 
and TP53I1, therefore producing immunosuppressive effects under hypoxia [18]. 
More recently, miR-210 was reported to be involved in activation and differentiation of 
T cells, especially the TH17 subset of helper T cells (TH17 cells), consequently limiting 
the associated immunopathology [77]. 
Regulatory T cells (Tregs, a subset of T cells with immunosuppressive 
characteristics) are especially crucial for preventing autoimmune diseases and 
controlling chronic inflammatory illnesses [78]. One study has provided compelling 
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evidence that marked downregulation of miR-210 is one of the miRNA signatures of 
circulating CD4(+) Tregs from healthy adult subjects, and the transcription factor 
forkhead box P3 (FOXP3, mandatory for Treg cell function) is negatively modulated 
by miR-210 [79]. However, significant upregulation of miR-210 has been observed in 
CD4(+) T cells from patients with psoriasis vulgaris , and this led to damage of 
immunosuppressive function of Treg cells by directly targeting FOXP3 [80]. 
In addition to T cells, role of miR-210 in B cells has also been proposed. 
Overexpression of Oct-2-induced miR-210 after B cell activation can significantly 
inhibit production of age-associated autoantibodies, and also lead to abnormal B cell 
subsets and function, especially cell autonomous expansion of B1 lineage and 
damaged fitness of B2 cells [34]. Another study demonstrates that miR-210 driven by 
lipopolysaccharide (LPS), a new feedback negative player in LPS/Toll-Like Receptor 
4 (TLR4) pathway, can decrease LPS-induced production of pro-inflammatory 
cytokines in murine macrophages; this is mediated by repressing NFκB1 , attenuating 
inflammatory responses and regulating immune responses [81]. These data may 
imply that miR-210 acts as a negative regulator in the prevention of age-associated 
autoimmunity.  
As noted above, extensive studies have provided substantial evidence for miR-210 
as a multifaceted mediator in cellular biology by regulating numerous signaling 
pathways, but its effects may depend on the specific physio-pathological context. 
Despite all this progress, the molecular mechanisms underpinning miR-210 regulation 
and function remain to be elucidated. 
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5. Roles for miR-210 in human diseases 
5.1 Roles for miR-210 in cardiovascular and cerebrovascular diseases (CCVDs) 
Table 1 outlines the role of miR-210 in CCVDs. Emerging technologies have 
promoted the study of miRNAs and their association with diseases [82]. To date, 
miR-210 stands out as the specific hypoxamir reported in almost cells studied, thus its 
induction may directly reflect the hypoxic state that is involved in a wide range of 
human diseases.  
Over the last decade, miR-210 has attracted tremendous interest as a crucial 
epigenetic regulator of physiological and pathological events in cardiovascular system. 
Theoretically, release of miR-210 from endothelium in clinically healthy subjects with 
low maximal oxygen uptake (VO2max) may function as a novel early marker of 
cardiovascular disease (CVD) because this miRNA is related to subclinical 
artherosclerosis, hypoxia or inflammation [43]. Given miR-210 augmentation in low 
VO2max set and significant correlation between them, miR-210 may be a promising 
biomarker of aerobic fitness level [43]. As a master hypoxamir, miR-210 is a 
well-characterized hypoxia-induced miRNA in ischemic cardiovascular diseases, such 
as MI [83], heart failure (HF) [84] and arteriosclerosis obliterans (ASO) [85]. Moreover, 
miR-210 is also identified as a potential stroke marker. miR-210 levels at different 
times was remarkably decreased in blood from stroke patients in contrast to healthy 
controls [86]. On the contrary, significantly upregulated miR-210 was shown in adult 
rat ischemic brain cortexes, which triggered the Notch pathway, leading to the 
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compensatory angiogenesis after cerebral ischemia [87].  
Furthermore, White et al. [88] have observed miR-210 upregulation in lungs from 
multiple distinct pulmonary hypertension (PH) models including a genetic model, a 
chronic hypoxia-induced PH model, hypoxia/Sugen model, and inflammatory PH 
models. The authors also validated that chronic activation of miR-210-ISCU1/2 
regulatory axis could cause a reduction in Fe-S clusters in vivo and promote the 
evolution of PH. Since the level of miR-210 can differentiate between the low and high 
VO2max groups, which cannot be separated by the traditional risk factors, miR-210 
may represent an early marker of CCVD risk even beyond traditional risk factors [88]. 
However, the specificity of miR-210 in detecting CCVD may be limited as many 
hypoxic conditions can influence its expression. 
5.2 Roles for miR-210 in tumour biology 
 Based on the crucial roles of miRNAs in cancer initiation, progression and 
dissemination , many studies have explored the specific role of miR-210 in 
pathogenesis of malignancies [89] (Table 2). Certain microRNAs, known as 
oncomiRNAs, play a causal role in the onset and maintenance of cancer when 
overexpressed [90]. Currently, overwhelming data have identified miR-210 as an 
oncogenic miRNA in a wide range of human malignancies including pancreatic cancer, 
breast cancer, lung cancer, B cell malignancies, and hepatocellular carcinoma (HCC) 
[13, 14, 32, 91, 92]. Similarly, elevated expression of miR-210 has been detected in 
SDHB and VHL-mutated tumours including clear cell renal cell cancer (CCRCC), PCs, 
PGLs, and GISTs [30, 45]. Additionally, aberrant overexpression of miR-210 may 
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change normal fibroblasts into cancer associated fibroblasts (CAFs), which boosts 
aggressiveness of prostate tumour cells through driving epithelial to mesenchymal 
transition , supporting angiogenesis [93]. Foekens et al. has connected miR-210 to 
metastatic capability in estrogen receptor-positive/lymph node-negative breast cancer 
[70]. Furthermore, a mouse model of left and median bile duct ligation has shown 
increased expression of miR-210 that contributes to progression of 
cholestasis-accelerated cholangiocarcinoma (CCA) by MNT downregulation [31].  
 In contrast to above solid tumours, miR-210 is frequently reported to downregulate 
in esophageal squamous cell carcinoma (ESCC) and ovarian cancer cell lines and to 
generate a tumour-suppressor effect [47, 48]. Consistent with this, 
inflammation-induced silencing of miR-210 may augment cell proliferation, contribute 
to induction of helicobacter pylori -associated gastric diseases including cancer [52] . 
Several studies implicate a critical role of miR-210 in reducing cancer cell proliferation 
by repressing targets, such as E2F3 [27, 47]. A mouse xenograft model in an elegant 
study performed by Huang X et al. robustly demonstrated that miR-210 could 
suppress tumour growth initiation of head and neck tumour [12]. Hence it is not 
surprising that miR-210 is also likely a tumour-suppressive microRNA unfavorable to 
tumour onset and growth in some tumour circumstances.  
In addition to upregulated or downregulated miR-210 in multiple tumour types, there 
may be no change in miR-210 expression in some tumours, for example, head and 
neck squamous cell carcinoma (HNSCC) [94]. Many different tumours frequently 
present with different levels of miR-210 expression，probably because expression of 
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miR-210 serves as a marker for tumour hypoxia [12, 94] that is extremely diverse in a 
variety of cancers. Possibly, deleted miR-210 genomic region is another explanation 
[44].   
 Because of inherent stability and good accessibility of circulating miRNAs [95], 
miR-210 can be an attractive candidate biomarker for diagnosis. Additionally, 
dysregulated miRNA expression partly represents the early event in tumourigenesis 
and In circulating miRNAs present unique profiles for each tumour and 
histopathological subtype [96]. In line with these findings, altered serum or plasma 
miR-210 may serve as a promising diagnostic biomarker for patients with 
malignancies, such as diffuse large B-cell lymphoma, CCRCC and pancreatic cancer 
[91, 97, 98]. Furthermore, to diagnose a disease, a specific pattern consisting of more 
than one miRNA, such as miR-210 combined with other miRNAs, may improve the 
power for differential diagnosis . For example, this could help to discriminate between 
pancreatic adenocarcinoma patients and controls [99], acute lymphoblastic leukemia 
(ALL) and acute myeloid leukemia (AML) [100], lung tumours and benign solitary 
pulmonary nodules (SPNs) [101], early stage diffuse-type gastric cancers (DGCs) and 
normal ones [102], and among grade IV, grade II and III astrocytomas [103]. For the 
first time, Eissa et al. [104] proposed a strategy for bladder cancer (BC) diagnosis 
which combines miR-210 with other two miRNAs in urine, superior to the urine 
cytology in sensitivity. Although these findings indicate the possibility of using 
circulating miR-210 as a biomarker for an early tumour diagnosis, specificity and 
sensitivity of diagnostics, standardization of blood sampling and analysis protocols to 
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make it’s a routine clinical test, are still in infancy.  
So far, the prognostic value of miR-210 expression in cancers has been widely 
investigated. Data from clinical cancer samples has elucidated that miR-210 
upregulation is an independent prognostic factor of poor survival in multiple cancers 
including breast cancer, colorectal cancer (CRC), and pediatric osteosarcoma [14, 
105, 106]. When combined with other miRNAs, miR-210 can be a more specific and 
accurate prognostic indicator for pancreatic ductal adenocarcinomas (PDAC) and 
glioblastoma patients [13, 107]. Similar results can be observed in head and neck 
cancer [94]. Since miR-210 is a significant element of chronic hypoxia irrespective of 
androgen dependency, it could be detected as a prognostic marker in high risk 
patients with prostate cancer [108]. Meanwhile, Tsang and colleagues [45] have 
substantiated miR-210 as a robust marker for pseudohypoxia (i.e. hypoxia gene 
expression despite normoxic conditions) in SDHB- and VHL-mutated PC/PGLs, which 
occurs even before tumour development.. Paradoxically, a recent study has revealed 
that patients with significantly lower expression of miR-210 tend to relapse and 
present with induction failure, even poorer treatment outcome in pediatric ALL [109]. 
McCormick et al. [30] have provided strong evidence that in CCRCC, increased 
miR-210 is associated with better prognosis. In non-small cell lung cancer (NSCLC) 
patients, highly expressed miR-210 in both cancer cells and stromal cells acts as a 
positive prognosticator with an improved disease-specific survival (DSS) [110]. 
miR-210 is also associated with poor prognosis in soft-tissue sarcoma (STS) [111]. 
On the other hand, ectopic expression of mir-210 represses tumour growth in human 
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head and neck or pancreatic tumours [12]. miR-210 could provide added value to 
other current diagnostic laboratory tests for cancers such as CCRCC where miR-210 
level is significantly increased. With the use of next generation sequencing, miR-210 
may be useful in monitoring the disease outcome over time. 
Taken together, these data imply the dual roles of an oncomiRNA and a 
tumour-suppressive microRNA for miR-210, which may depend on tumour types or its 
different stages or tumour microenvironment. Further studies are required to clarify 
tissue- and cell type-specific profiles of miR-210. Although miR-210 has a potential 
value in prediction, prognosis, and treatment of cancer, it is still a long way to go 
before clinical applications.  
5.3 Roles for miR-210 in other diseases 
In addition to CCVD and tumour, the abundant data on miR-210 also shed light on 
further investigating the mechanisms of other human diseases as summarized in 
Table 3. A recentstudy suggests that upregulated miR-210 is likely to participate in the 
formation of gallstones by inhibiting Homo sapiens ATPase, class VI, type 11A 
(ATP11A, a novel ABC transporter homolog) [112]. Similar robust induction of 
miR-210 is proved to be involved in radiation-induced enteropathy. Interestingly, the 
miR-210 inhibitor showed an anti-fibrotic action by decreasing collagen I (Col Ia1) 
mRNA expression in fibrotic cells [113]. In addition, elevated plasma miR-210 levels in 
patients with acute kidney injury (AKI) may serve as an independent and powerful 
predictor of survival in critically ill patients with AKI [114]. In keeping with these 
findings, the attenuation of apoptosis via miR-210/SHIP-1/Akt pathway may contribute 
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to progression of MDS and hence miR-210 may serve as such a marker [60]. Lemaire 
and colleagues [115] have reported that the first 24h of Leishmania infection shows a 
rapid and significant alteration of miRNA profile of human primary macrophages, 
especially the progressive and robust increase of miR-210.  While miR-210 has been 
identified as a significantly upregulated microRNA in periodontitis patients with obesity 
[116], downregulation of miR-210 by > 2-fold has been demonstrated in diseased 
gingiva compared to healthy gingival tissues [117]. However the biological 
significance of miR-210 aberration involved therein is poorly understood. 
Additionally, accumulating evidence suggests that miR-210 is significantly involved 
in the erythroid phenotype. Kosaka et al.[118] reported that increased expression of 
miR-210 following erythroid differentiation in UT-7/erythropoietin (EPO) cells as well 
as in murine fetal liver erythroid cell differentiation in vitro, indicating that miR-210 is 
likely to be correlated to erythroid maturation. Similar results was found in the 
erythroid precursor cells from patients exhibiting hereditary persistence of fetal 
hemoglobin (HPFH), along with enhanced expression of the fetal γ-globin genes [119]. 
Sarakul et al. further confirmed that under hypoxia, miR-210 was elevated in both 
K562 and β-thalassemic erythroid progenitor cells, whereas miR-210 blockade 
inhibited these events [120]. However, downregulation of miR-210 can be surprisingly 
observed following erythroid induction of both K562 cells and CD34+ cells derived 
from human cord blood [121]. These data support a vital role of miR-210 in erythroid 
maturation, proliferation, and even γ-globin gene expression.  
To date, overexpression of miR-210 in the syncytiotrophoblasts of preeclampsia 
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(PE) placentas has been increasingly reported by different groups , especially in 
severe PE [122]. The upregulated miR-210 may participate in occurrence of PE via 
reduction of trophoblast invasion by downregulating Ephrin-A3, Homeobox-A9, 
potassium channel modulatory factor 1 (KCMF1) [123, 124]. Currently, miR-210 has 
already been identified as a potential serum biomarker for PE , and miR-210 inhibition 
may promisingly ameliorate symptoms of PE. In addition to PE placenta, miR-210 
expression is also significantly enhanced in placentas of maternal obesity in a fetal 
sex-dependent manner, thus resulting in repression of mitochondrial respiration and 
dysfunction of placenta [37]. Despite these recent advances, the mechanisms of 
miR-210 upregulation and downregulation, its target biomolecules as well as its 
pathophysiological roles in these diseases remain to be established. 
 
6. A promising therapeutic target for miR-210 
Given the fact that silencing aberrantly miRNAs in vivo has been achieved using 
antisense with a diversity of nucleic acid analogues such as 29-O-methyl 
oligonucleotides (for example, antagomiRs), locked nucleic acids (LNAs), and peptide 
nucleic acids (PNAs) or nanoencapsulated [125-127], miR-210 has garnered interest 
as a possible therapeutic target for human diseases in the last decade. Indeed, 
strategies for adjusting the aberrantly expressed miR-210 may provide a new 
therapeutic avenue for various diseases. Probably, one of the most exciting 
opportunities is potential use of miR-210 mimics or antagonists as therapeutics. For 
example, miR-210 has been knockdown by using a lentiviral-mediated antisense 
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miR-210 gene transfer technique, which may eliminate glioma stem cells (GSCs) 
located in hypoxic niches [128]. Since in vivo efficacy of current antagomiR 
techniques is impeded by physiological and cellular barriers to deliver into targeted 
cells, Cheng et al. [90] have created a novel antagomiR delivery platform that targets 
the acidic tumour microenvironment, evades systemic clearance by livers, and 
facilitates cell entry via a non-endocytic pathway. Additionally, plant extract may be 
another choice for inhibiting miR-210. For example, Difluorinated-Curcumin (CDF), a 
novel synthetic analog of curcumin derived from the perennial herb Curcuma longa, 
with greater bio-availability in multiple tissues, , may function as a robust antitumour 
agent against prostate cancer in vitro and in vivo, at least partly by negatively 
regulating miR-210 [129].  
On the other hand, miR-210 mimic treatment can ameliorate cardiac dysfunction of 
ischemic heart disease [29]. Based on the importance of miR-210 in 
Akt/HIF1α-regulated cell survival, vector-based and ex-vivo stem-cell-based delivery 
of miR-210 has been performed for myocardial repair with encouraging results [130]. 
By using real-time PCR and histological analysis techniques, a study in a rat model 
has shown the effect of intra-articular injection of miR-210 on ligament healing [131]. 
The same technique has also produced a desired effect in accelerating avascular 
meniscal healing in rat medial meniscal injured model [132]. Since oligonucleotides or 
virus based constructs can systemically reintroduce a tumour-suppressor miRNA into 
cancer cells so as to repress tumour growth [133], miR-210 may be a favorable future 
treatment approach for ESCC patients. Forced overexpression of miR-210 may lead 
D
ow
nl
oa
de
d 
by
 [U
CS
F L
ibr
ary
] a
t 0
8:0
0 0
3 J
uly
 20
16
 
26 
 
to downregulation of Prolyl 4-hydroxylase, beta polypeptide (P4HB) and a reduction in 
temozolomide (TMZ)-resistance in cultured glioblastoma multiforme (GBM) cells and 
a reciprocal relationship between miR-210 and P4HB expression was also confirmed 
in clinical glioma specimens [134]. Moreover, miR-210 may have therapeutic 
applications in terms of cancer immunotherapy in view of its influence on tumour cell 
susceptibility to CTL-mediated lysis [18]. Meanwhile, targeting HIF-1α by 
administrating miR-210 mimics in vivo may be useful for TH17 cell-dependent 
autoimmune diseases because miR-210 is a potent regulator of HIF-1α in T cells [77]. 
Additionally, (-)-epigallocatechin-3-gallate (EGCG, green tea polyphenol) treatment 
can contribute to induction of miR-210, and then negatively regulate cell growth of 
human and mouse lung cancer [28]. Furthermore, WSS25 (a heparan sulfate mimetic) 
may be a promising drug applicable in angiogenesis in terms of targeting miR-210 
[73]. In targeted delivery of miRNA-210 for cancer treatment, the types of cancer must 
be taken into consideration as the expression level and function of miR-210 vary 
among different types of cancer. Although manipulating miR-210 expression or 
function may have an effect on experimental models of diseases (especially 
carcinomas, autoimmune diseases, and injury disorders), and miR-210 has a 
potential role in human disease therapy, successful implementation of miR-210 
therapeutics still requires more in vitro and in vivo experiments are required to 
research the safety and feasibility of agomiR-210 and antagomiR-210 in clinical 
application.  
Despite these promises, the limitations of using miR-210 as a therapeutic target 
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must be recognized and there are also obstacles on the way for the successful 
delivery of miRNA. One issue is the systemic effect of miR-210, as the molecule has a 
diverse effect on multiple systems. Another challenge is targeted delivery to a specific 
organ or tissue. The antisense strategies for in vivo delivery with nucleic acid 
analogues have the problem of non-specific organ bio-distribution and clearance by 
reticuloendothelial system and the liver. Cheng’s new antimiR delivery approach 
targeting the acidic environment can only apply to the drug cargo with limited charge 
such as PNA118. There is still distribution to other acidic tissue environment, for 
example the kidney. Many of the miRNA approaches remain to be tested using in vivo 
models and over a long term with a view of assessing unknown side effects. The 
safety and efficacy in humans remain to be evaluated. 
 
7. Conclusion 
miR-210 has already been shown to be involved in sophisticated regulation of 
numerous biological processes almost throughout the human body. This 
multi-functional hypoxamir is proved to be correlated with the pathophysiology of 
different diseases, including tumours, CCVDs, immunological diseases, and PE. 
Among these diseases, miR-210 expression is frequently upregulated, and functions 
as an oncogene. Contradictory phenomenon for miR-210 is exhibited in other 
diseases, which mostly suggests miR-210 a protector against diseases. Importantly, 
circulating miR-210 seems to have great theranostic potential for future clinical 
practice. It can not only serve as a potent biomarker for diagnosis, disease 
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progression and patient prognosis, but also serve as a good theranostic target for 
treatment. However, it is worth noting that miR-210 therapeutics is a double-edged 
sword, further work remains required to improve its efficacy. In summary, the 
characteristics of miR-210 make it an attractive therapeutic candidate, and its real 
value will most likely be determined in the very near future. 
 
8. Expert opinion 
8.1 Identification of roles of miR-210 in disease diagnosis 
Nowadays, the gold standard for cancer detection is the histological evaluation of 
biopsy because of its high sensitivity and specificity. But its usage is still restricted to 
clinical settings because of the suffering of patients resulting from the invasive nature 
[135]. Since deregulated miRNA expression is an early event in tumourigenesis, 
measuring circulating miR-210 levels has already shown promise as a noninvasive 
biomarker for early cancer detection without the unpleasant procedure [97, 98]. 
However, the application of miR-210 as an effective clinical biomarker still has a long 
way to go. 
Firstly, although many studies investigated the important diagnostic value of 
miR-210 in various cancers, these studies often reached conflicting results due to the 
limited sample size, different study design, and lack of unified standard [135]. In 
addition, except cancers, studies related to miR-210 as an effective screening 
strategy in other human diseases are relatively sparse. More studies with better 
design and larger sample sizes are urgently needed for this task. Secondly, recent 
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studies suggested that hypoxic condition, a hallmark of virtually all solid cancers, may 
induce the expression of miR-210 by HIF-1a [27, 28, 135]. Although such connection 
of miR-210 and cancer opens the door for using miR-210 as a hypoxia marker for 
tumours, the exact mechanism in tumour development needs further investigation. 
Thirdly, there seems to be a general agreement that single miR-210 can cover a 
broad spectrum of neoplasms and the combination of miR-210 and other miRNAs 
may contribute to significant improvement in specificity [101, 102], but the 
combination approach, as well as the unique indicator for specific cancer, pose 
significant challenges. 
 
8.2 Emerging roles of miR-210 in disease prognosis 
A multitude of studies have firmly established the relationship between miR-210 
and cancers, for instance, pancreatic tumour, breast cancer, glioblastoma, and CRC 
[13, 14, 70, 105]. Overexpression of miR-210 has been consistently linked to adverse 
prognosis in multiple solid tumour types, including CRC and pediatric osteosarcoma 
patients [105, 106], while expression of miR-210 in clear cell renal cell cancer 
(CCRCC) associated with a favorable prognosis [30]. Therefore, the impact of 
miR-210 on cancer prognosis still needs detailed studies and the results of existing 
researches may not be applicable for other carcinomas. Furthermore, the role of 
miR-210 in routine clinical management of cancer remains unevaluated. More clinical 
investigations with long follow-up period should be carried out before the practical 
application of miR-210 in prognosis of diseases [136]. 
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8.3 Therapeutic potential of miR-210 in diseases  
For the vast majority of tumours, chemotherapy or radiation therapy is still the 
cornerstone of treatment. Monoclonal antibodies only have little benefits in a limited 
proportion of patients. However drugs frequently face well-known clinical issues 
related to variable responses, toxicity and drug resistance. These issues highlight the 
urgent demand for the development of novel anti-cancer drugs . As an important class 
of gene regulators, miRNAs, in particular miR-210, possess high potential for 
anti-cancer therapeutic development. Nevertheless, from basic researches to clinical 
application, there is still a huge gap so far due to a number of limitations and 
challenges. Therefore, it is suggested that more research should be conducted along 
the following approaches to pave the way for miR-210 clinical application. 
 Currently, miR-210 has been identified as a member of a pan-cancer oncogenic 
microRNA ‘superfamily’ which shares a central GUGC core motif resulting in 
cotargeting critical tumour suppressors [137]. Hence therapeutically suppressing 
miR-210 may encounter compensation from other superfamily members yielding poor 
results and how to evaluate and handle this compensation is also a great challenge. 
To date, it is not fully understood whether miR-210 likely constitutes other oncomiRNA 
networks and plays greater roles. Additionally, determining accurate genomewide 
miR-210-target interactions is another difficult question to address. On the other hand, 
multidrug resistance (MDR) should be taken into account because it is a major clinical 
obstacle to the successful treatment of malignant diseases, but the underlying 
mechanisms remain unclear. A better understanding of the mechanisms may achieve 
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optimized therapy. Recently, emerging evidence suggests the contribution of hypoxia 
to drug resistance in a wide spectrum of neoplastic cells, in which HIF-1 has been 
widely studied, plays an important role [138]. As a hypoxamir, miR-210 is likely to play 
an important role in the process of MDR via regulation of its numerous targets, which 
remains to be prospectively validated. Reportedly, miR-210 may be a marker of 
radiotherapy resistance and offer the possibility of developing more efficient 
therapeutic strategies [94]. Trastuzumab resistance has been proved to be a major 
issue in antihuman epidermal growth factor receptor 2 therapy for breast cancer [139]. 
The levels of circulating miR-210 have been reported to correlate with trastuzumab 
sensitivity and tumour presence in patients with breast cancer [140], suggesting that 
plasma miR-210 may help identify subsets of patients who can benefit from such 
agents, and even serve as a potential novel patient selection criteria for clinical trials 
in the future. It is conceivable that miR-210 in combination with other anti-cancer 
therapies could contribute greatly to the success of cancer treatment, but further work 
will be required . The possibility that inactivation of miRNAs involved in hypoxic 
adaptation may be a viable strategy , poses significant therapeutic challenges. 
Therefore, a complete understanding of miR-210 regulatory architecture and net 
production will help develop more efficient therapeutic strategies for human diseases. 
A series of in vitro and in vivo experiments and bioinformatics analysis are needed, 
and with improvements in drug delivery technology，will enable miR-210-mediated 
therapy to open a new era. 
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Table 1 Roles of miR-210 in CCVDs 
CCVD Expression Function of miR-210 Reference 
CVD Up Overexpressed miR-210 can be used as a novel biomarker of fitness level and future CVD. [43] 
MI Up miR-210 is highly upregulated during in MI. [83] 
HF Up miR-210 is one of the upregulated miRNAs in HF. [84] 
ASO Up miR-210 significantly increases in both sclerotic and serum samples. [85] 
Stroke 
Down or 
Up 
As blood miR-210 levels at different times are remarkably decreased, miR-210 may be as a 
potential stroke marker. 
Conversely, significantly upregulated miR-210 can trigger the Notch pathway, contributing to 
angiogenesis after cerebral ischemia. 
[86, 87] 
PH Up Chronic activation of miR-210-ISCU1/2 regulatory axis can promote the evolution of PH. [88] 
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Table 2 Roles of miR-210 in tumours 
Tumour Expression Function of miR-210 
Referenc
e 
Head and neck 
tumour 
Up or no 
difference 
Ectopic expression of miR-210 can inhibit the tumour growth initiation of head and neck 
tumour. 
In HNSCC, no difference of miR-210 expression is observed between HNSCC tissues and 
control ones, whereas tumour miR-210 expression is an adverse prognostic factor. 
miR-210 is capable to differentiate grade IV from grade II and III astrocytomas. 
[12, 94, 
103] 
ESCC Down 
Downregulation of miR-210in human ESCC, especially in poorly differentiated carcinomas 
can function as a tumour-suppressive microRNA with effects on cancer cell proliferation 
through FGFRL1. 
[47] 
Lung cancer Up 
miR-210 overexpressed in late stages of lung cancer mediates mitochondrial alterations, 
which correlates with modulation of HIF-1 activity. 
[32, 110] 
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Tumour Expression Function of miR-210 
Referenc
e 
In NSCLC, high expression of miR-210 is a positive prognostic factor for DSS. 
Breast cancer Up 
Overexpression of miR-210 indicates worse prognosis, especially in triple- negative primary 
breast cancers.  
miR-210 combined with other three miRNAs (miR-7, miR-128a, and miR-516-3p) links to 
ER(+)/LNN breast cancer aggressiveness.  
Plasma miR-210 may possibly predict and monitor response to trastuzumab for breast 
cancer patients. 
[14, 70, 
140] 
GC Up Circulating miR-210 can accurately detect DGC at an early stage. [102] 
HCC Up Hypoxia/miR-210/VMP1 pathway regulates hypoxia-induced HCC cell metastasis. [92] 
CCA Up 
Activation of HIF-2α-miR-210-MNT pathway leads to cyclin D1 upregulation, thus regulating 
the chronic cholestasis accelerated progression of CCA. 
[31] 
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Tumour Expression Function of miR-210 
Referenc
e 
Pancreatic cancer Up 
Elevated miR-210 plays an oncogenic role in the development of pancreatic cancer and is 
associated with poorer survival. 
Circulating miR-210 might serve as a novel biomarker of this disease. 
[13, 98, 
99] 
PC, PGL, and GIST Up miR-210 is upregulated in SDH- or VHL-mutated tumours. [45] 
CRC Up 
Hypoxia-inducible miR-210 is a useful biomarker and an independent prognostic factor that 
contributes to cancer metastasis. 
[105] 
CCCRC Up 
Elevated serum miR-210 is associated with better clinico-pathological prognostic factors and 
may be a promising biomarker for detecting CCRCC. 
[30, 97] 
BC Up miR-210 in urine is one of the potential miRNA signatures for BC. [104] 
Prostate cancer Up 
miR-210 expression may augment when prostate cancer cells were exposed to hypoxia, 
therefore it may be useful for high risk prostate cancer patients, irrespective of the androgen 
[93, 108, 
129] 
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Tumour Expression Function of miR-210 
Referenc
e 
dependency.  
miR-210 overexpression can increase senescence-associated features for young fibroblasts 
and convert them into CAF-like cells, thus promoting cancer progression.  
Prostate cancer may be treated at least partly due to by CDF negatively regulating miR-210. 
Ovarian cancer Down 
High frequency of miR-210 gene copy deletions contributes to causing low expression of 
miR-210. 
[48] 
B cell malignancies Up 
Levels of serum miR-210 are higher in diffuse large B-cell lymphoma (DLBCL) patients than 
healthy controls, acting as diagnostic biomarkers. 
[91] 
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Tumour Expression Function of miR-210 
Referenc
e 
Pediatric ALL Down Lower expression of miR-210 suggests worse prognosis and poorer treatment outcome. [109] 
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Table 3 Roles of miR-210 in other diseases 
Disease Expression Function of miR-210 
Referenc
e 
Gallstone Up miR-210 likely participates in the formation of gallstones by inhibiting ATP11A. [112] 
Radiation enteropathy Up miR-210 is likely involved in radiation-induced enteropathy. [113] 
AKI Up 
Increased plasma levels of miR-210 may be as an independent and powerful predictor of 
survival in critically ill patients with AKI. 
[114] 
Obese periodontitis Up miR-210 is one of the significantly upregulated microRNAs. [116] 
Diseased gingiva Down Downregulation of miR-210 has been demonstrated in diseased compare to healthy gingiva. [117] 
MDS Up miR-210/SHIP-1/Akt pathway attenuating apoptosis may be involved in progression of MDS. [60] 
Leishmania infection Up 
miR-210 abundance is progressively and robustly increased throughout the time course of 
infection. 
[115] 
PE Up As a potential serum biomarker, overexpression of miR-210 may participate in occurrence of [37, 
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PE by downregulating ephrin-A3, HOXA9, and KCMF1. 
It is especially correlated with severe PE. 
122-124] 
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Figure 1 Regulation of miR-210 expression. The figure 
summarizes how miR-210 expression may be regulated or 
influenced. Sharp arrows indicate activation/upregulation and 
double arrows indicate interaction between them. 
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Figure 2 Regulation of signaling pathways by miR-210: miR-210 regulates several key 
biological processes including proliferation, apoptosis, DNA repair, angiogenesis and immune 
responses via the action of a vast variety of transcription factors and inflammatory mediators. 
Sharp arrows suggest stimulatory effects whereas blunt arrows are inhibitory. 
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Figure 3 miR-210 and immune response miR-210 regulates both acquired and 
inmate immune responses, via its action on hypoxia-mediate pathway, 
transcription factors, and cytokines. 
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